Drug intelligence / Profile preview

IMC-2017

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Implant

Overview

IMC-2017 is a preclinical-stage stem cell therapy candidate developed by ImmuneCyte Life Sciences. It is designed for use in spinal fusion (SF) procedures to enhance bone healing and fusion rates. The therapy is produced using ImmuneCyte's proprietary AutoSTEM platform, which focuses on the automated and standardized production of stem cell products. The program is currently in the preclinical or pilot phase of development.

Beyond the preview

Go deeper on IMC-2017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-2017.

Explore the full profile